loading
Rhythm Pharmaceuticals Inc stock is traded at $88.30, with a volume of 666.96K. It is up +3.60% in the last 24 hours and up +34.93% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$85.23
Open:
$85.14
24h Volume:
666.96K
Relative Volume:
0.95
Market Cap:
$5.62B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-31.42
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+2.14%
1M Performance:
+34.93%
6M Performance:
+48.58%
1Y Performance:
+88.51%
1-Day Range:
Value
$84.39
$88.42
1-Week Range:
Value
$83.98
$88.42
52-Week Range:
Value
$40.61
$94.80

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Name
Rhythm Pharmaceuticals Inc
Name
Phone
857-264-4280
Name
Address
222 BERKELEY STREET, BOSTON, MA
Name
Employee
283
Name
Twitter
@rhythmpharma
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
RYTM's Discussions on Twitter

Compare RYTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
88.30 5.62B 136.86M -168.69M -113.49M -2.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Initiated Goldman Buy
Jul-07-25 Initiated Leerink Partners Outperform
Apr-07-25 Upgrade BofA Securities Neutral → Buy
Mar-05-25 Resumed Stifel Buy
Jan-02-25 Initiated Jefferies Buy
Dec-20-24 Initiated Oppenheimer Outperform
Oct-21-24 Initiated Guggenheim Buy
Sep-18-24 Initiated H.C. Wainwright Buy
Sep-17-24 Initiated JMP Securities Mkt Outperform
May-08-24 Downgrade BofA Securities Buy → Neutral
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-01-23 Upgrade BofA Securities Neutral → Buy
Jan-18-23 Resumed Canaccord Genuity Buy
Aug-08-22 Upgrade Goldman Neutral → Buy
Aug-05-22 Upgrade BofA Securities Underperform → Neutral
Jun-17-22 Reiterated Needham Buy
Mar-02-22 Resumed Stifel Buy
Feb-17-22 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-08-21 Initiated Wells Fargo Overweight
Nov-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-14-21 Resumed Goldman Neutral
Aug-04-21 Downgrade BofA Securities Neutral → Underperform
Aug-04-21 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-30-20 Downgrade BofA Securities Buy → Neutral
Jan-08-20 Initiated Goldman Sell
Jul-12-19 Upgrade Stifel Hold → Buy
Jul-08-19 Initiated Canaccord Genuity Buy
Mar-13-19 Initiated Ladenburg Thalmann Buy
Sep-07-18 Resumed Morgan Stanley Overweight
Jun-25-18 Reiterated Needham Buy
Jun-15-18 Reiterated Needham Buy
Oct-30-17 Initiated BofA/Merrill Buy
Oct-30-17 Initiated Needham Buy
View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

pulisher
Aug 01, 2025

How does Rhythm Pharmaceuticals Inc. generate profit in a changing economyFinancial News Forecasts For Smart Trading - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

Is it the right time to buy Rhythm Pharmaceuticals Inc. stockSmart Portfolio Data Feed For 2025 - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) - Insider Monkey

Aug 01, 2025
pulisher
Jul 30, 2025

Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - 富途牛牛

Jul 30, 2025
pulisher
Jul 29, 2025

Rhythm pharmaceuticals exec Cramer sells $130k in shares By Investing.com - Investing.com India

Jul 29, 2025
pulisher
Jul 29, 2025

Cramer, Rhythm Pharmaceuticals’ CHRO, sells $130k in shares By Investing.com - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Rhythm pharmaceuticals exec Cramer sells $130k in shares - Investing.com Australia

Jul 29, 2025
pulisher
Jul 29, 2025

Rhythm Pharmaceuticals Inc. At Decision Level — Rebound or ResistanceCapital Preserving Trade Plan Templates Shared - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 21:10:10 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline - Yahoo Finance

Jul 29, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-29 04:03:24 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Trendline Breach Raises Concern for Rhythm Pharmaceuticals Inc. InvestorsChart Driven High Reward Trading Setup Presented - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What are the latest earnings results for Rhythm Pharmaceuticals Inc.Expert Picks Insights For Fast Growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What is Rhythm Pharmaceuticals Inc. company’s growth strategyFree Stock Market Return Analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is Rhythm Pharmaceuticals Inc. stock overvalued or undervaluedInvest with confidence backed by data - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Rhythm Pharmaceuticals Inc. stock attracting strong analyst attentionCapitalize on market momentum for profits - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetIdentify breakout stocks before they peak - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells - MSN

Jul 28, 2025
pulisher
Jul 27, 2025

Is Rhythm Pharmaceuticals Inc. a growth stock or a value stockFree Stock Market Return Analysis - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

When is Rhythm Pharmaceuticals Inc. stock expected to show significant growthGet daily expert analysis on top stocks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-27 20:42:04 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-27 06:42:10 - metal.it

Jul 27, 2025
pulisher
Jul 25, 2025

What drives Rhythm Pharmaceuticals Inc. stock priceTriple-digit wealth increases - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable trading performance - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Is Rhythm Pharmaceuticals Inc. a good long term investmentDouble-digit growth - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool

Jul 21, 2025
pulisher
Jul 20, 2025

Rhythm Pharmaceuticals prices $175M stock offering - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru

Jul 19, 2025
pulisher
Jul 19, 2025

Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AOL.com

Jul 19, 2025

Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):